Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;79(4 Suppl 2):S116-20.
doi: 10.1097/TA.0000000000000740.

Preclinical evaluation of injectable reduced hydroxocobalamin as an antidote to acute carbon monoxide poisoning

Affiliations

Preclinical evaluation of injectable reduced hydroxocobalamin as an antidote to acute carbon monoxide poisoning

Joseph D Roderique et al. J Trauma Acute Care Surg. 2015 Oct.

Abstract

Background: Current management of acute inhalational carbon monoxide (CO) toxicity includes hyperbaric or normobaric O2 therapy. However, efficacy has not been established. The purpose of this study was to establish therapeutic proof of concept for a novel injectable antidote consisting of the combination of hydroxocobalamin and ascorbic acid into a reduced form (B12r) as demonstrated by clinically significant increase (>500 ppm) in CO2 production, reduced carboxyhemoglobin (COHgb) half-life (COHgb t1/2), and increased cerebral O2 delivery and attenuation of CO-induced microglial damage in a preclinical rodent model of CO toxicity.

Methods: B12r-mediated conversion of CO to CO2 and COHgb t1/2 in human blood were measured by gas analysis and Raman resonance spectroscopy. Rats were exposed to either air or CO and then injected with saline or B12r. Cognitive assessment was tested in a Morris water maze. Brain oxygenation was measured with Licox. Brain histology was assessed by fluorescent antibody markers and cell counts.

Results: B12r resulted in significant CO2 production (1,170 ppm), compared with controls. COHgb t1/2 was reduced from 33 minutes (normal saline) to 17.5 (p < 0.001). In rat models, severe CO-induced brain hypoxia (PbtO2, 18 mm Hg) was followed by significant reduction in τ25 to 12 minutes for B12r rats versus 40 minutes for normal saline-treated rats (p < 0.0001). There was major attenuation of CO-induced microglial damage, although cognitive performance differences were minimal.

Conclusion: Our preclinical data suggest that the novel synergism of hydroxocobalamin with ascorbic acid has the potential to extract CO through conversion to CO2, independently of high-flow or high-pressure O2. This resulted in a clinically significant off-gassing of CO2 at levels five to eight times greater than those of controls, a clinically significant reduction in COHgb half-life, and evidence of increased brain oxygenation and amelioration of myoglial damage in rat models. Reduced hydroxocobalamin has major potential as an injectable antidote for CO toxicity.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Comparative CO2 production (ppm/min) over 30 min induced by B12r antidote (hydroxocobalamin B12 +ascorbic acid) added to whole human blood containing 50% COHgb. The shaded area is the difference between CO2 produced from ascorbic acid alone, and that produced by B12r. Little or no CO2 was produced by infusion of normal saline (NS) or oxidized hydroxocobalamin.
Fig. 2
Fig. 2
Brain oxygen tension (PbtO2, mmHg) measured in 30 Sprague-Dawley rats exposed to medical air (AIR) or CO, and injected with either saline (NS) or antidote (B12r). Solid lines are fitted equations; dotted lines show estimated threshold τ25 for each CO-exposure treatment.
Fig. 3
Fig. 3
Median path efficiencies (straight line distance/observed swim path length) for rats exposed to medical air (SHAM) or CO and injected with either NS (CO-NS) or antidote (COB12) and tested in a Morris Water maze over 8 days.
Fig. 4
Fig. 4
Immunochemistry of brain tissue of rats exposed to medical air (CONTROL) or CO with either antidote (B12r) or NS control solution. A. Mean (SD) microglial and astrocyte cell counts of GFAP and Iba-1 tagged cells; B. Relative myelination: Myelinated axons are indicated by white arrows. Note the paucity of myelin in the CO poisoned rats (center panel); C. Microglial activation. Yellow arrows highlight activated microglia based on increased Iba-1 staining density, thickened processes, and loss of arborization.
Fig. 4
Fig. 4
Immunochemistry of brain tissue of rats exposed to medical air (CONTROL) or CO with either antidote (B12r) or NS control solution. A. Mean (SD) microglial and astrocyte cell counts of GFAP and Iba-1 tagged cells; B. Relative myelination: Myelinated axons are indicated by white arrows. Note the paucity of myelin in the CO poisoned rats (center panel); C. Microglial activation. Yellow arrows highlight activated microglia based on increased Iba-1 staining density, thickened processes, and loss of arborization.

References

    1. Mowry JB, Spyker DA, Cantilena LR, Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol Phila PA. 2013;51:949–1229. - PubMed
    1. Bhatia R, Chacko F, Lal V, Mittal BR. Reversible delayed neuropsychiatric syndrome following acute carbon monoxide exposure. Indian J Occup Environ Med. 2007;11:80–82. - PMC - PubMed
    1. Buckley NA, Juurlink DN, Isbister G, Bennett MH, Lavonas EJ. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database of Systematic Reviews. 2011;(4) doi: 10.1002/14651858.CD002041.pub3. Art. No.: CD002041. - DOI - PMC - PubMed
    1. Buckley NA, Juurlink DN. Carbon monoxide treatment guidelines must acknowledge the limitations of the existing evidence. Am J Respir Crit Care Med. 2013;187:390. - PubMed
    1. Schrauzer GN, Lee LP. The reduction of vitamin B12a by carbon monoxide. Arch Biochem Biophy. 1970;138:16–25. - PubMed

Publication types